Introduction
In recent years a large amount of data has been gathered on the biology of thyroid hormone receptors. The receptor proteins have been analyzed from the physiological and structural points of view. Most of the information has been summarized in several recent excellent reviews (1-6). The thyroid hormone receptors (TR) are ligand-modulated transcription factors which are members of a large superfamily that includes nuclear receptors for other small, hydrophobic molecules such as steroids, vitamin D 3 , retinoic acid, prostaglandins, terpenoids, farnesoids and fatty acids, and also the so-called orphan receptors with no recognizable ligand. They bind triiodothyronine (T 3 ) with an affinity about 10 times higher than thyroxine (T 4 ) and activate or repress gene expression upon ligand binding. In addition, an important property of the thyroid hormone receptors is their ability to influence gene expression in the absence of the hormone. In most cases this is reflected in a repression of the target genes which is relieved upon ligand binding, although there are also examples of ligand-independent stimulation of transcription. Little is known of the biological consequences of this intrinsic receptor property. The repressor activity of mutated T 3 receptors that have lost the ability to bind hormone is considered to play a role in the pathogenesis of the thyroid hormone resistance syndromes. Receptor expression during development precedes the onset of fetal thyroid function and, with the reservations imposed by placental transfer of maternal thyroid hormone, the unliganded receptor might influence fetal development through mechanisms that are at present unknown. To shed light on this problem, we and others have analyzed the influence of exogenous T 3 receptor expression on the phenotype of cultured cells which express no or little T 3 receptors unless engineered to do so. The purpose of this review is to summarize the available data in this direction and to try to formulate an hypothesis concerning receptor function.
Thyroid hormone receptor genes
Thyroid receptors are the product of two genes, designated TRa and TRb, located in different chromosomes (17 and 3 respectively, in humans). The original cloning of the receptor included the chicken a type and the human b type (7, 8) . Cloning of the receptor was achieved thanks to its homology to v-erbA, an oncogene present in the genome of the avian erythroblastosis virus which is involved in the generation of chicken erythroleukemias and sarcomas. TR genes encode several receptor isoforms. Thus the TRa gene gives rise by alternative splicing to TRa-1, TRa-2 and, by expression of the alternative strand, Rev-ErbAa. TXa-2 differs from TRa-1 in its carboxy terminus and is also known as c-ErbAa-2 or TR variant a-2 (TRva-2) because, like Rev-Erba, it does not bind hormone and therefore cannot be considered as a receptor. In transfected cells c-ErbAa-2 is able to inhibit transcriptional activation by TRa-1 and TRb-1 (9, 10). The mechanism of this effect remains undefined and may involve competition for DNA binding sites, for retinoid X receptor (RXR), or for other nuclear factors (11, 12). However, recent data indicate that cells expressing high levels of TRva-2 do respond to the gene induction activity of T 3 (13). v-ErbA represents a mutated form of the TRa subtype that behaves as a constitutive transcriptional repressor of genes activated by hormone-activated TR (14, 15). The products of the TRb gene are TRb-1 and TRb-2, which arise through the use of alternative promoters and differ in their aminoterminal sequence. This scheme is valid for humans and rodents. In neither the chicken nor amphibia has a TRva-2 been identified. The product of TRa gene in the chicken is a single TRa mRNA which is translated into two proteins, TRa-p46 and the truncated TRa-p40, through the use of two alternative translational start sites (16, 17) . No TRb-1 has been identified in the chicken: instead the products of the chicken TRb gene are two proteins, TRb-0 and TRb-2, with TRb-0 having a very short amino terminus (18). In amphibia there are two TRa and two TRb receptor genes designated TRa-A, TRa-B, TRb-A and TRb-B, which are the origin of six TRa and three TRb protein isoforms (19).
The T 3 receptors, as with other receptors that are transcription factors, modulate transcription mainly by binding to specific DNA acceptor sites known as T 3 response elements (T 3 RE). These consist of repeats of the basic hexameric consensus sequence AGGT/ACA in several different arrangements such as direct repeats separated by a 4 bp spacer (DR4) as in the T 3 RE present in rat malic enzyme (20) and cardiac heavy myosin alpha chain (21), everted repeats separated by 6 bp (ER6), as in chicken lysozyme (22) and rat myelin basic protein (23), and other configurations. In the most prevalent model of T 3 action the TRs act as heterodimers with RXR, the 9-cis retinoic acid receptor. Both biochemical and structural studies have shown that the TR-RXR heterodimer binds to the T 3 RE with a polarity such that the TR sits on the 3 0 half site (24). In the absence of T 3 the receptor has an intrinsic transcriptional repressor function. Hormone binding is followed by conformational changes that have effects on the interaction with the basal transcriptional machinery, with stabilization and/or recruitment of basal transcription factors and a stimulation of transcription. T 3 can also inhibit transcription as shown for the a and b subunits of thyrotropin (TSH) genes in the pituitary gland (25, 26), b-myosin heavy chain gene in the heart (27), neuronal cell adhesion molecule (NCAM) gene in the brain (28) and skeletal muscle (29) or glutathione-S-transferase in the liver (30). (Information on thyroid hormone receptors can be found on the Internet at the following URL: http://www.xanadu.mgh.harvard.edu/ receptor/trrfront.html)
Receptor-associated factors
In addition to the RXR partner, many other molecules have been shown to be directly or indirectly associated functionally to the TR. In most cases these associations provide not only a mechanistic explanation of how thyroid hormone ultimately affects transcriptional activity, but they also represent links with many other signaling pathways that allow the integration of diverse physiological signals. At the first level is the RXR-TR heterodimer. Since RXR is a receptor itself, and also a partner for other nuclear receptors, its engagement in other activation pathways may modify the cellular response to T 3 . For instance, mutual interference between vitamin D 3 and T 3 signaling has been described (31, 32). TRs form heterodimers with other members of the receptor superfamily such as vitamin D 3 receptor or the peroxisome proliferator-activated receptor (PPAR) (33, 34), and their activity can be modulated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) and perhaps other orphan receptors binding to analogous DNA sequences (35, 36) . At the second level the RXR-TR heterodimer acts through adaptor molecules recently discovered which are known as corepressors or coactivators (for reviews see 37, 38) . Corepressors are proteins that mediate the ligand-independent function of the receptor, by making inhibitory interactions with the transcription machinery. Two corepressor molecules have been described, N-CoR (nuclear receptor corepressor, p270) and SMRT (silencing mediator for RARs and TRs, or p165) (39, 40) . Upon ligand binding the corepressors leave the complex, derepressing gene expression. Subsequently, coactivators are recruited causing the activation of gene transcription. These proteins act as bridging factors between the receptors and the basal transcription factors. Several coactivators for steroid/thyroid receptors have been described such as TR-interacting protein1/transcriptional intermediary factor 1 (Trip1/ TIF1), receptor-interacting protein 140 (RIP140), steroid receptor co-activator-1/nuclear-coactivator-1 (SRC-1/N-CoA1) and the TRAP complex (for a recent review see 41) . Another important coactivator is the mouse CREB-binding protein (CBP) and the closely related human p300. These proteins interact with thyroid, steroid and retinoic acid receptors, as well as many other transcription factors, such as phosphorylated CREB, c-Jun, c-Fos, c-Myb, Elk-1, etc. Because CBP and p300 are at the crossroads of many diverse signals, they have been considered as integrator molecules (42, 43) . In fact, it has been proposed that the mutual antagonism between activating protein-1 (AP-1): JunFos and activated hormone receptors is due to competition for limiting amounts of CBP/p300 in the nucleus (43) . It has also been suggested that some coactivators, including CBP/p300 have histone acetyltransferase activity and that their role is to destabilize nucleosomes through an increased acetylation of histones, which can make DNA more accessible to transcription factors (44) . Conversely, the N-CoR corepressor has been found to form a complex with histone deacetylase (45) .
Receptor domains
Several domains have been described that mediate the biological activity of thyroid hormone receptors ( Fig. 1) : the amino-terminal (A/B) domain, the DNA binding domain (C), the hinge domain (D), and the ligand binding/carboxy-terminal domain (E/F). Some of these domains are well conserved among the different receptor isoforms, and even among different nuclear receptors. In the past two years the structures of the DNA and ligand binding domains have been solved by X-ray crystallography (46, 47) .
The amino-terminal domain is involved in transcriptional activation. Its sequence is highly divergent between the alpha and beta receptor subtypes and between the beta receptor isoforms suggesting differences in transcriptional activity. The TRb-1 and TRb-2 isoforms have an identical sequence throughout the molecule except for the amino-terminal portion of the protein. This divergence in sequence arises through the use of alternative promoters, yielding two proteins which have different tissue expression and biological activities in spite of having identical DNA and ligand binding domains. The amino-terminal domain is thought to be involved in transcriptional activation independently of the ligand. Its action appears to be mediated through interaction with components of the basal transcription machinery, specifically with transcription factor IIB (TFIIB) (48, 49) . Deletion of amino acids 21 to 30 of chicken TRa decreases the activating capacity by 10-to 20-fold (50) . Though this region does not contain an intrinsic activation domain, it is important for interaction with TFIIB. A role of the amino-terminal domain has also been described for modulation of functional interactions with corepressors. While this region is not directly involved in binding the nuclear corepressors, a differential effect of the corepressor on the ligand-independent repression or activation has been described between TRa-1 and TRb-1 on the one hand and TRb-2 on the other (51) . The amino-terminal region of TRb-2 precludes the formation of functional interactions with N-CoR, either through conformational changes of the receptor or through the association with specific coactivators. The amino-terminal domain may also play a role in DNA recognition (52) .
The DNA binding domain is the most conserved region among nuclear receptors. It contains two characteristic DNA binding modules, arranged as the so-called zinc fingers. The C-terminal portion of the first zinc finger is an alpha helix known as the DNA recognition helix because it interacts with specific DNA sequences. This helix contains lysine and arginine residues that contact the guanines in the T 3 RE half site. Discrimination of response elements also depends on three amino acids (EGG, in the TRs) which are essential for recognition of natural T 3 REs and constitute the socalled P (for 'proximal') box. Mutations of the P box amino acids alter little the recognition of the half site sequence AGGTCA, but affect binding of receptor to the sequence AGGACA, which is much more commonly found among natural T 3 REs. This is partly the reason why v-erbA in which glycine is substituted for a serine in the third position of the P box is not able to bind to the AGGACA sequence, but binds well to the AGGTCA motif (53) . Downstream of the second zinc finger there are two other regions of helical structure known as T and A boxes. The T box was previously demonstrated in RXR to play a role in the cooperative binding of RXR homodimers to DR1 motifs (AGGTCA half sites separated by 1 base). In the TR, the T box provides contact with the N-terminal region of the second zinc finger of RXR. The A box was first described in the transcription factor NGFI-B, also an orphan member of the nuclear receptor family, where it plays a role in the recognition of additional A residues located 5 0 to the binding site, facilitating monomer binding. As pointed out by Rastinejad et al. (46) , the A-helix of TR stabilizes the DNA binding domain on the DNA with a more extensive recognition interface than for steroid receptors, conferring the TR with the ability to bind as monomers and to recognize octamer response elements (54) . The A box determines the specific recognition of the two nucleotides T(A/G) at the 5 0 -end of the octamer. The hinge (D) domain is a stretch of amino acids that links the DNA and ligand binding domains which are conserved between TRa and TRb. Its functions are not well known: formerly, a role in nuclear targeting of the receptor molecule was proposed (55) , and more recently it has been found to participate in the association with corepressor proteins (39) .
The E/F domain (ligand binding domain, or LBD) is mainly a-helical in structure, with 12 a helices assembled in three layers leaving an internal hydrophobic pocket where the ligand is buried (47) . In addition to ligand binding it also has important roles in receptor dimerization, and in the interaction with cofactors. There are three distinct subregions within the ligand binding domain, which are known as tau i (t i ), the ninth heptad, and AF-2 (tau-c or tau-4) respectively. The t i subregion, near the N-terminus of the LBD, is well conserved among nuclear receptors and is probably involved in protein-protein interactions. The ninth heptad (amino acids 368 to 374 of rTRa) is involved in receptor dimerization (12, 56, 57) . Some amino acid residues within this region have been shown to be critical for receptor function. For example, mutations of the critical leucine in codon 428 of hTRb-1 selectively abolishes heterodimerization with RXR and dominant negative activity. The AF-2 subregion comprises the 17 amino acids located in the carboxy terminus of TR (58, 59) . It has autonomous activation function and consists of a highly conserved amphipathic a-helix required for ligand-dependent activation of the receptor. The fact that the hormone is buried inside a hydrophobic cavity within the ligand binding domain suggests that the conformational changes associated with ligand binding affects the surface of the receptor, exposing critical residues located in the AF-2 subregion involved in protein-protein interactions important in transcriptional activation (47) .
Hormone-independent activities of TR
In addition to their capacity to activate gene transcription upon hormone binding, it is becoming progressively clear from several studies that unliganded TR exert biological actions. The most obvious is the repression of the basal transcription probably as a consequence of the recruitment of corepressors. On the other hand, unliganded TR can also upregulate the expression of some genes putatively inhibited by T 3 . For instance, chicken TRa and also v-erbA activate the promoter regions of several human keratin genes (60) , and mouse TRb-1 activates the promoter regions of the mouse preprothyrotropin-releasing hormone gene in transfected cells (61) . RXR heterodimerization seems to be dispensable for this activity of unliganded TR.
Chicken TRb-2 has a strong ligand-independent transactivation activity on a subset of response elements (62) . Rat TRa-1 is also able to activate transcription in a T 3 -independent fashion in pituitary GH4C1 cells but not in several other cell lines (63, 64) . In addition, the regulatory regions of the Rous sarcoma virus and human immunodeficiency virus type 1 are activated in transfected cells by TRa-1, but not TRb-1, independently of T 3 (65, 66) . The mechanism of these T 3 -independent effects is probably the formation of direct protein-protein interactions with the transcription initiation machinery or with other nuclear factors, which may also be used to modulate distinct signaling pathways controlled by different factors (AP-1, CREB) as mentioned above.
How can this activity of TR be regulated? A possibility, speculative and not yet demonstrated, is the control of their phosphorylation status. Very early, both chicken TR and v-ErbA proteins were shown to be substrates of kinases (protein kinase (PK) C, PKA, casein kinase II) in vitro and in vivo (67, 68) . Phosphorylation of specific serine residues in the amino-terminal domain of v-ErbA is essential for its oncogenic potential, while in the homologous chicken TR/c-ErbA protein it may be required for the transcriptional repressor activity (69) . Indirect results using non-specific phosphatase inhibitors such as okadaic acid suggest that T 3 -induced transcriptional activation of rat TRa-1 and TRb-1 is modulated by phosphorylation (70) . Furthermore, using this same inhibitor phosphorylation has been demonstrated to be essential for the interaction between human TRb-1 and RXRb (71) . More importantly, okadaic acid-induced phosphorylation of human TRb-1 stimulates its transcriptional activity in transfected cells and increases its ability to bind DNA and other nuclear proteins in vitro (72) . Recently, okadaic acid has been shown to selectively increase the stability of TRb-1 protein in COS cells but not in other cell types (73) .
As discussed, the biological activities of Rev-ErbAa and perhaps also c-ErbAa-2 variants might also be based on protein-protein interactions perhaps regulated by phosphorylation. In favor of this idea, the DNA binding activity of c-ErbAa-2 is modulated by phosphorylation which, in turn, may affect its negative regulation of TRa-1 receptors (74) .
The c-erbA proto-oncogene mediates the gene regulatory activity of thyroid hormone
The product of the c-erbA proto-oncogene (chicken TRa gene) was initially characterized as a nuclear protein able to bind T 3 with a high affinity and specificity both in vitro and in transiently-transfected cells (7, 8). In addition, it showed the size proposed in biochemical studies existing in the literature for the thyroid receptor. The ultimate identification of the c-erbA protein as the functional thyroid receptor, however, needed the demonstration that it could mediate the physiological action of the hormone. To accomplish this, the c-erbA proto-oncogene was introduced and expressed in the FAO rat hepatoma cell line using recombinant retroviruses. This cell line was chosen because it is devoid of endogenous thyroid receptors and thus insensitive to thyroid hormone. FAO cells expressing c-ErbA, but not parental cells or those expressing the mutant v-ErbA protein became hormone-dependent in terms of induction of some liver genes such as malic enzyme, phosphoenolpyruvate carboxykinase, and Na + /K + -ATPase known to be thyroid-responsive (75) . By following this genetic complementation approach, the c-ErbA-a protein was definitively identified as the functional receptor mediating the gene regulatory activity of T 3 .
Established cell lines often express very low amounts of active thyroid receptors with some exceptions. The reason for this may be, though not demonstrated, a silencing process perhaps due to methylation of TR genes following in vitro culture. Also, expression of high levels of the TRa-2 variant would, in theory, block the effects of any residual receptor. To demonstrate any effects of TR and of T 3 in cultured cell lines of diverse origin we and others have used a technique of genetic complementation similar to the one applied to demonstrate that the c-ErbA protein was indeed able to transduce T 3 responses in hepatoma cells, as described above. These studies have proven very useful in gaining insight into the T 3 -dependent and -independent effects of TRs in several tissues. In the following sections we will summarize the most relevant data obtained.
Effects of TRs in neuronal cells
Thyroid hormone has profound effects on brain development in humans and rodents. The patterns of expression of different sets of TR isoforms in a timeand region-specific fashion in the brain are complex (for reviews on T 3 effects in the brain see 76, 77) . Some neuronal populations of the hypothyroid brain are arrested in their terminal differentiation. In addition, there are studies suggesting a cooperation between T 3 and nerve growth factor (NGF) in the development of the hippocampus, cerebellum and olfactory bulb, and in the activity of neural marker enzymes in the basal forebrain in the early postnatal rat brain (78, 79) . These data were the basis for the analysis of the effect of TR-a in PC12 cells. The main conclusions of these studies are shown schematically in Fig. 2 .
PC12 cells are rat pheochromocytoma cells which show characteristics of adrenal medulla neuroendocrine progenitors. They display a dual differentiation capacity, either into sympathetic neurons upon induction with NGF, or into secretory chromaffin cells upon treatment with glucocorticoid hormones. The ability to follow a complete gene expression program which leads them to change their phenotype towards that of sympathetic neurons makes PC12 cells the most popular system in which to study neuronal differentiation in response to a neurotropic factor.
PC12 cells expressing the chicken TR-a gene (PC12+TRa-1) from an integrated Moloney murine leukemia-based retrovirus showed a very interesting phenotype: they were able to respond to the initial steps of the neuronal differentiation triggered by NGF with expression of a series of immediate early genes (c-jun, junB, junD, c-fos, fra-1, NGFI-A, NGFI-B) and formation of short processes (spikes), but were, however, blocked in later phases of differentiation with no elongation of neurites and the inhibition of the expression of the NGFinduced neuronal genes (transin, SCG10, neurofilament-68, NCAM, GAP43) (80) . Thus, in the absence of hormone TR expression causes an inhibition of the NGFinduced neuronal differentiation pathway. Remarkably, co-treatment of PC12+TRa-1 cells with NGF and T 3 leads to the release of this repression and full acquisition of the neuronal phenotype.
Also interestingly, addition of T 3 alone to these cells leads to cell death by apoptosis showing that an increase in TR makes the cells strictly dependent on neurotropins for survival. None of these phenomena take place in cells expressing the mutant v-erbA gene: PC12+v-erbA cells are constitutively inhibited to differentiate into neurons either in the absence or in the presence of hormone. In line with the inability of the v-ErbA protein to bind T 3 , addition of hormone cannot release the repression of the NGF-induced neuronal differentiation. Besides this, T 3 does not affect the viability of PC12+v-erbA cells (80) .
These results suggest the intriguing possibility that expression of TR in vivo can modulate the response of neural precursor cells to neurotropins. Depending on the amount of thyroid receptors expressed, the fate of neuroblasts might be differentiation (if both T 3 and neurotropins are available), death (if T 3 levels are normal but there is a lack of neurotropins) or limited/ delay in maturation (in the case of hypothyroidism).
The alternative differentiation pathway of PC12 cells into chromaffin cells is also affected by TR expression. Increased TR levels cause a blockade in the basal and also the glucocorticoid-induced expression of tyrosine hydroxylase, the key enzyme in catecholamine synthesis. Again, v-erbA leads to an aberrant situation with an abnormally elevated expression of chromaffin markers (tyrosine hydroxylase, chromogranin B). This TR action is independent of T 3 , and agrees with a role of TR in inducing the commitment of undifferentiated progenitor cells to follow the neuronal pathway. For this, two signals appear to be required: the permissive one provided by T 3 , and the differentiating one provided by neurotropins (NGF). It is of obvious interest to investigate whether similar or different mechanisms of cooperation between T 3 and NGF or other neurotropins are functional in the differentiation of neurons in the central nervous system. In fact, preliminary results from our laboratory suggest that this can be the case.
Mouse N2a neuroblastoma cells constitute another model system used for biochemical studies of neuronal function. These cells show morphological differentiation with formation of neurites upon serum removal, which can be enhanced by retinoic acid, cAMP, and other factors. They express very low amounts of TR and consequently are insensitive to T 3 . Exogenous expression of TR genes in N2a cells has been carried out by two groups. Pastor et al. (81) showed that stable expression of the chicken TR-a leads to a T 3 -independent increase in trkB RNA levels which is concomitant with a decrease in the amount of trkA and trkC RNAs. BDNF, the trkB ligand, induced trkB autophosphorylation, but not cell differentiation possibly because the cells lacked some component of the normal chain of events triggered by neurotropins. Transient expression of rat TRa-1 and TRb-1 in these cells causes the same effect, suggesting that TR themselves could be involved in the regulation of the particular set of neurotropin receptors expressed by some neuronal groups during embryonic development. The lack of T 3 effect on trkB mRNA agrees with in vivo data that show no changes in the content of the different trkB RNA species in the neonatal or adult hypothyroid rodent brain when analyzed by Northern blotting or in situ hybridization (82) (83) (84) .
Puymirat and Dussault have expressed the human TRb-1 and rat TRa-1 genes in N2a cells. T 3 treatment of cells expressing TRb-1, but not of those expressing TRa-1 blocks proliferation and induces morphological differentiation. T 3 enhances acetylcholinesterase mRNA levels and enzymatic activity in the cells (85, 86) . It is unclear whether the differences found in these studies reflect different roles for TR subtypes or differences in the levels of expression achieved by the respective genes.
Effects of TRs in glial cells
An extensive literature exists indicating that both types of glial cells, oligodendrocytes and astrocytes, are targets of T 3 in vivo and express several TR isoforms. Multiple studies have indicated that myelination by oligodendrocytes and also several differentiation parameters of astrocytes are affected by T 3 deprivation in rodents. However, data from Oppenheimer's group have recently challenged this idea by showing that rat brain astrocytes in situ do not express appreciable TR (87) . These data agree with our finding that expression of astrocyte-specific genes such as glial fibrillary acidic protein (GFAP) and glutamine synthetase are not changed in neonatal hypothyroidism (88) . Thyroid hormone might cause indirect actions mediated by neurons or oligodendrocytes, or even act through extragenomic pathways. An example of the latter has indeed already been described: T 4 regulates deiodinase activity by affecting actin polymerization (89) .
To analyze possible roles of TR in a glial cell context we first used C6 glioma cells to investigate the regulation of myelin genes by TR and T 3 . Surprisingly, T 3 caused only a minor increase in proteolipid protein (PLP) RNA levels in cells over-expressing the chicken TR-a gene (90) . In contrast, retinoic acid (RA) had a dramatic effect increasing PLP RNA levels in parental C6 cells, and also in those overexpressing TR-a or verbA. The MBP and MAG genes encoding the other two major myelin proteins (Myelin Basic Protein, Myelin Associated Glycoprotein) were silent in C6 cells. Another T 3 -target gene, the b1-adrenergic receptor (b1-AR) was not responsive to T 3 in C6 cells, even after expression of T 3 receptor in amounts that were able to confer T 3 -dependency to the enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) synthase (91) . The b1-AR gene is transcriptionally regulated by T 3 in other cell types such as cardiac myocytes, and a down-regulation of the number of b1-and b2-AR in the hypothyroid brain has been reported (92-94). Since our retrovirally-infected C6 cells showed a high TRa-1/c-erbAa-2 ratio, T 3 unresponsiveness cannot be attributed to a blocking effect of TRa-2 but is probably due to intrinsic cell type-specific factors. These experiments suggest an important role for cofactors (presumably coactivators or corepressors) in determining cell specificity on the physiological actions of T 3 .
We have studied TR effects in another cell line of glial origin called B3.1. These cells were established from embryonal day 10 mouse brain by infecting primary total brain cultures with a v-myc-expressing retrovirus (95) . Clonal B3.1 cells express genes of undifferentiated glial precursors such as A2B5, laminin and vimentin together with astrocytic genes such as GFAP, and also the CNP gene encoding the early myelin enzyme 2 0 , 3 0 -cyclic nucleotide phosphodiesterase, but no genes for other mature myelin proteins or neuronal markers. Consequently, they can be considered as of mixed/ precursor glial phenotype. Although these cells initially expressed TRb-1, TRa-1, and c-erbAa-2, the expression of TRb-1 was lost upon time in culture. Exogenous expression of the chicken TRa gene resulted in an increased TRa-1/c-erbAa-2 ratio and an enhanced cellular responsiveness to T 3 . Two astrocytic genes, vimentin and GFAP, were down-regulated by T 3 in B3.1+TRa-1 cells but not in parental B3.1 or B3.1+v-erbA cells, a result that supports a direct effect of T 3 in this cell type. Perhaps the divergence of these data from those obtained in Northern blots from total brain showing no differences in astrocytic genes between control and hypothyroid rats may be due to regional effects of T 3 , as suggested from the analysis of hypothyroid rat brains and experiments using primary astrocytic cultures (96) (97) (98) . In contrast, the expression of CNP gene was basically unaffected in these two latter cell types but abolished in B3.1+v-erbA cells (95) . These results indicated the functionality of the exogenous TR genes in B3.1 cells, and a role for T 3 in the control of glial cell differentiation in vivo.
More drastic was, however, the action of TR genes on B3.1 cell survival and proliferation (Fig. 3) . In serumcontaining medium B3.1+TRa-1 cells grew at a slower rate than parental cells, whereas B3.1+v-erbA cells displayed an enhanced proliferation capacity (95) . These differences were more clear when the cells were cultured in serum-free conditions. Survival in defined N2 medium was strongly reduced in the case of B3.1+TRa-1 cells, which rapidly degenerated and entered into an apoptotic process with chromatin condensation and cytoplasmic disorganization. This process could be inhibited by protein kinase C activators and bcl-2 overexpression, and it is currently under investigation in our laboratory (S Llanos, C Caelles, I Azorin, J Renau-Piqueras, JL Fernández-Luna, L Boscá & A Muñ oz, unpublished observations).
In contrast, B3.1+v-erbA cells are able to survive for weeks in the absence of serum, and grow rapidly to confluency in the presence of insulin or insulin-like growth factor-I (IGF-I) (99) . We checked the hypothesis that v-erbA could be inducing the expression of a growth factor, and indeed we found that B3.1+v-erbA cells express and secrete active platelet-derived growth factor (PDGF) BB (99) . The use of specific antibodies allowed the confirmation that the PDGF R-b is constitutively autophosphorylated in B3.1+v-erbA cells and that in the presence of insulin or IGF-I, the induced PDGF BB is responsible for cell survival and growth acting in an autocrine fashion. In contrast, TRa-1 inhibits the basal expression of PDGF BB in B3.1 cells, and consequently no phosphorylation of the PDGF R-b is detected in B3.1+TRa-1 cells.
Further studies led to the finding that at least two parameters of cell transformation were also induced by v-erbA in B3.1 cells: invasiveness in vitro and anchorage-independent growth (100). The former is fully dependent on the induction of PDGF BB, while additional factor(s) present in the serum are needed to overcome the growth restriction due to the lack of anchorage to a solid substrate. Basic fibroblast growth factor (bFGF) is a strong candidate to be one of these factors. The study of a long series of genes putatively involved in the acquisition of cell malignancy led to the finding that the c-jun and fra-1 oncogenes are overexpressed in B3.1+v-erbA cells in serum-free conditions. The exact role played by these two genes in the biological effects observed as causative or consequence of PDGF action is still an unresolved matter. Given the proposed importance that autocrine and paracrine PDGF loops can have in the development of gliomas in rodent and in humans, these results suggest the possibility that alterations in TR/erbA genes may be involved in these tumors, and stress the interest in the analysis of the integrity and expression of TR genes in tumor biopsies.
Interestingly, in chicken neuroretina cells v-erbA alone is not transforming but a cooperation between v-erbA and bFGF causes cell transformation (101) . In view of its action in B3.1 cells, the possibility exists that v-erbA may be inducing a factor(s) which synergizes with bFGF. As discussed below when reviewing v-erbA effects on chicken erythroblasts, the cooperation between v-erbA and tyrosine kinase oncogenes or over-activated normal kinase receptors as those for bFGF can be a widespread mechanism of cell transformation.
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Effects of TRs in erythroblasts
The identification of the v-erbA oncogene present in the genome of the avian erythroblastosis virus (AEV) as a mutated form of TRa-1 focussed the attention on the action of both normal and mutated receptors on the proliferation and differentiation of erythroblasts. The AEV contains a second oncogene, v-erbB, which encodes an altered, constitutively active version of the epidermal growth factor (EGF-R). This fact links membrane tyrosine kinase and nuclear hormone receptors in the control of cell fate.
Mutational and biological studies have demonstrated that v-erbB is the primary oncogene of AEV responsible for the deregulation of cell proliferation, and that the action of v-erbA is mainly to block terminal differentiation of chicken erythroblasts (see 102, 103 for reviews). Although a transforming activity in vitro of v-erbA alone has been proposed (104) no definitive conclusions can be drawn, and it seems probable that v-erbA has no major effect on the self-renewal capacity of erythroblast progenitors. Both oncogenes, v-erbA and v-erbB clearly cooperate in inducing full cellular transformation in vitro and leukemia in vivo.
At least three genes, carbonic anhydrase II (CAII), the anion transporter band 3, and d-aminolevulinate synthase, have been identified as targets of v-erbA in chicken erythroblasts (105, 106) . These genes, which are transcriptionally inhibited by v-erbA, control key steps in erythroblast cell physiology concerning exchange of gases and anions, and the synthesis of the heme group. Since their re-expression by introduction of exogenous genes (CAII, band 3) does not result in the recovery of the differentiated phenotype, it can be assumed that other important, still unknown v-erbA target genes in these cells must exist (107) .
Obviously, the possibility that v-erbA blocks the biological activity of normal TR in chicken erythroblasts acting as a dominant negative receptor was first investigated. However, the situation became rapidly more complex than expected. Unliganded TRa-1 was unable to block cell differentiation even if overexpressed, causing only a delay in maturation (103) . In the presence of T 3 , TRa-1 was a strong inducer of commitment, differentiation and growth arrest of erythroid precursors in the presence of differentiating agents (insulin, erythropoietin) opposing v-erbA action in a dominant manner (108) . In the absence of differentiating agents, liganded TR and also RA receptor (RAR) induce apoptosis, while v-erbA exerts an opposite protective effect from apoptosis (109) . These results and the analysis of its multiple mutations led to the idea that v-erbA may affect genes and pathways independent of those regulated by normal TRs. In favor of this, in vitro studies have shown that the DNA binding capacity of the v-ErbA protein differs from that of normal TRs, and the study of mutants have confirmed the critical importance of the DNA binding specificity for v-erbA function (53, 110, 111) . It is conceivable that v-ErbA can act not only as a repressor of T 3 -activated genes but also as a constitutive activator of other genes perhaps via a transactivation domain located in its N-terminal region. Supporting this, phosphorylation of two serines in positions 18/19 is essential for its transforming activity (69) .
Unexpectedly, estrogen and glucocorticoid hormones have been found to promote proliferation of chicken hematopoietic progenitors in collaboration with stem cell factor (SCF) and transforming growth factor (TGF)-a. Recent data indicate that v-ErbA can substitute for ligand-activated estrogen (ER) and glucocorticoid (GR) receptors in the induction of self-renewal of primary erythroid progenitors (102, 103 , and references therein). To effect this activity, v-ErbA also requires cooperation with activated tyrosine kinases such as cKit or c-ErbB, which respective ligands are SCF and EGF/ TGF-a. In summary, present knowledge indicates that in chickens v-ErbA arrests erythroblast differentiation, and induces proliferation and extended lifespan possibly by interfering with the activities of TRa and also ER and GR. However, available data on the effects of v-erbA transgenic mice (112) and on thyroid status in human patients do not support a major role of TR and T 3 in mammalian hematopoiesis.
Effect of TR on muscle cells
Together with other hormones such as retinoids and insulin-like growth factors, T 3 has profound effects of skeletal muscle cell differentiation in vivo. Its actions are mediated by direct regulation of some of the muscle master genes encoding key transcription factors, and also by control of other genes responsible for the biochemical and mechanical characteristics of these cells (113) . Genes controlled by T 3 include several members of the myosin heavy chain family, the Ca 2+ -ATPase, and the carbonic anhydrase III.
Carnac et al. (114) reported that T 3 acting through endogenous TRa-1 induces the transcription and protein expression of the myoD gene in a subclone of the mouse C2 myoblast cell line. MyoD is one of the master genes controlling myogenesis. This action is opposite to some growth factors (FGF, TGF-b) and oncogenes (ras, jun, fos) which negatively regulate myoD expression, and occurs in parallel with an acceleration of C2 cell terminal differentiation. A similar enhancement of myogenesis and myoD expression and arrest of proliferation was obtained by overexpressing the human TRb-1 gene in C2 cells, which also blocks the inhibitory action of AP-1 on myogenesis (115) . In these conditions, T 3 efficiently arrests cell proliferation and triggers terminal differentiation even in the presence of serum mitogens.
Following this finding, thyroid hormone response elements have been identified not only in the myoD gene but also in myogenin, another important myogenic gene, and skeletal a-actin gene. Interestingly, these three genes also contain binding sites for MEF-2 (Myocyte specific Enhancer Factor-2), another transcription factor, and both TR and MEF-2 have been proposed to synergistically regulate transcription via direct protein-protein interaction (116) .
Recently, the role of Rev-erbAa has been investigated in C2C12 myoblasts. Proliferating C2C12 cells express abundant levels of Rev-erbAa RNA, which decrease when C2C12 cells differentiate into postmitotic myotubes concomitantly with the induction of myogenin and a-actin RNAs (117) . Constitutive overexpression of rat Rev-erbAa abolished myogenic differentiation, and suppressed myoD RNA levels and myogenin RNA induction. Thus, Rev-ErbAa functions as a negative regulator of myogenesis by inhibiting T 3 activation through TRs of myogenic key genes such as myoD and myogenin.
Surprisingly, v-erbA has been described as stimulating quail myoblast terminal differentiation. Infection of secondary myoblast cultures with an v-erbA-retrovirus leads to a T 3 -independent increase in myogenesis (118) . Moreover, v-erbA does not affect T 3 action in these same cells nor does it act as a constitutive activator of myogenic genes such as myoD or myogenin. In addition, the authors of this study demonstrate that v-erbA action is dependent on the mutation present in the first zinc finger (Ser61) and propose the possibility that v-erbA may block the expression of genes inhibiting myoblast differentiation.
Effect of TR on mammary epithelial cells
Normal mammary epithelial cells express TRs and, consequently, mammary gland development and gene expression are responsive to T 3 (119, 120) . In contrast to other hormone receptors, breast cancer cells also express TRs (121, 122) . A huge and mostly contradictory literature exists on the relation between thyroid status or thyroid disease and breast cancer in humans (for reviews see [123] [124] [125] . To decipher putative effects of T 3 on mammary epithelial cells we have overexpressed the chicken TRa-1 gene in a normal, nontumorigenic mouse cell line called EpH4. These cells show a normal, polarized epithelial phenotype and contain only a basal number of TRs (126) .
EpH4+TRa-1 cells show a series of changes in respect to their progenitors. They respond to T 3 treatment with induction of protease genes such as stromelysin (ST)-1 and -2, and are also more sensitive to the induction of these proteases by growth factors such as TGF-a (120, M López-Barahona, JM González-Sancho & A Muñ oz, unpublished data). Zymography studies revealed that EpH4+TRa-1 cells respond to T 3 with secretion of active ST-1 and collagenase IVB into the extracellular medium. In addition, EpH4+TRa-1 cells partially lose their polarized expression of adhesive (catenins, fodrin) and extracellular matrix proteins (laminin, collagen IV) as shown by confocal microscopy. In line with this, T 3 treatment of EpH4+TRa-1 cell monolayers grown on porous filters leads to a rapid decrease in the transepithelial resistance. Furthermore, hormone addition causes the destruction of the three-dimensional networking structures formed by EpH4+TRa-1 cells in Matrigel or collagen gels (Fig. 4) . Together, these results suggest that overexpression of normal TRs has a deleterious effect for the maintenance of the normal polarized phenotype and morphogenetic potential of mammary epithelial cells.
TRa-1 overexpression also affects the proliferation capacity of EpH4 cells, making them sensitive to an inhibitory effect of T 3 (M López-Barahona, J González-Sancho & A Muñ oz, unpublished data). In summary, these studies demonstrate that overexpression of normal TRs affect the normal phenotype of mammary epithelial cells. and sophisticated transcription factors controlling, in a ligand-dependent and ligand-independent fashion, multiple gene networks involved in cell differentiation and physiology. The recent findings of an increasing number of TR heterodimerization partners, interacting proteins such as corepressors, coactivators and basal transcription components, and related receptors binding to homologous DNA sequences are amplifying and redefining their biological activities. Moreover, it is expected that the forthcoming analysis of the effects and control of their phosphorylation status will bring additional and possibly exciting insights into the roles of these highly interesting molecules in the growth, differentiation and physiology of a wide variety of cells in the organism. 
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